BIOMIND LABS INC.

Press Releases Biomind Labs Inc.

Equities

BMND.F

CA0907021012

End-of-day quote OTC Markets Other stock markets 03:30:00 04/04/2024 am IST			5-day change	1st Jan Change
0.11 ^USD	-.--%		-.--%	+10.00%

2023	Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	CI
2023	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canadian Investment Regulatory Organization Trading Halt - BMND	09/04	AQ
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	14/23/14	BU
Biomind Labs Announces the Completion of the First Sublingual Formulation for Its BMND08 Candidate for Depression and Anxiety in Alzheimer's Disease	29/22/29	AQ
Biomind and Queen's University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System	28/22/28	AQ
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression	26/22/26	BU
Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022	31/22/31	AQ
Biomind Labs Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression	09/22/09	BU
Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form	18/21/18	BU
Biomind Labs : to Advance a Phase II Clinical Trial on DMT for Treatment-Resistant Depression	18/21/18	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW